Defining the roles of arrestin2 and arrestin3 in vasoconstrictor receptor desensitization in hypertension

American Journal of Physiology - Cell Physiology

Volumn 309, Issue 3, 2015, Pages C179-C189

  Willets, Jonathon M ^a   Nash, Craig A ^a   Rainbow, Richard D ^b   Nelson, Carl P ^a   Challiss, R A John ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Arrestin; G protein coupled receptor; Hypertension; Phospholipase C; Resistance artery; Vasoconstrictor

Indexed keywords

ARRESTIN2; ARRESTIN3; ENDOTHELIN 1; G PROTEIN COUPLED RECEPTOR; INOSITOL 1,4,5 TRISPHOSPHATE; POTASSIUM; PURINERGIC P2Y RECEPTOR; RETINA S ANTIGEN; UNCLASSIFIED DRUG; URIDINE TRIPHOSPHATE; BETA ARRESTIN; VASOCONSTRICTOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HYPERTENSION; MALE; MESENTERIC ARTERY; MYOGRAPHY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; VASOCONSTRICTION; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; ORGAN CULTURE TECHNIQUE; PATHOLOGY; PHYSIOLOGY; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT;

ANIMALIA; RATTUS;

ANIMALS; ARRESTINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION; MALE; MESENTERIC ARTERIES; ORGAN CULTURE TECHNIQUES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 84938540756     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00079.2015     Document Type: Article

References (34)

1. Attramadal H, Arriza JL, Aoki C, Dawson TM, Codina J, Kwatra MM, Snyder SH, Caron MG, Lefkowitz RJ. ß-arrestin2, a novelmember of the arrestin/ß-arrestin gene family. J Biol Chem 267: 17882-17890, 1992.
2. Brinks HL, Eckhart AD. Regulation of GPCR signaling in hypertension. Biochim Biophys Acta 1802: 1268-1275, 2010.
3. Chen K, Fu C, Chen C, Liu L, Ren H, Han Y, Yang J, He D, Zhou L, Yang Z, Zhang L, Jose PA, Zeng C. Role of GRK4 in the regulation of arterial AT1 receptor in hypertension. Hypertension 63: 289-296, 2014.
4. 1D-adrenergic receptor constriction. Am J Physiol Heart Circ Physiol 295: H1695-H1704, 2008.
5. DeFea KA. Arrestins in actin reorganization and cell migration. Prog Mol Biol Transl Sci 118: 205-222, 2013.
6. Feldman RD, Gros R. Impaired vasodilator function in hypertension: the role of alterations in receptor-G protein coupling. Trends Cardiovasc Med 8: 297-305, 1998.
7. Grassi G. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens Res 29: 839-847, 2006.
8. Gros R, Benovic JL, Tan CM, Feldman RD. G-protein-coupled receptor kinase activity is increased in hypertension. J Clin Invest 99: 2087-2093, 1997.
9. Gros R, Chorazyczewski J, Meek MD, Benovic JL, Ferguson SS, Feldman RD. G-Protein-coupled receptor kinase activity in hypertension: increased vascular and lymphocyte G-protein receptor kinase-2 protein expression. Hypertension 35: 38-42, 2000.
10. Gros R, Ding Q, Chorazyczewski J, Andrews J, Pickering JG, Hegele RA, Feldman RD. The impact of blunted ßadrenergic responsiveness on growth regulatory pathways in hypertension. Mol Pharmacol 69: 317-327, 2006.
11. Harper S, Webb TE, Charlton SJ, Ng LL, Boarder MR. Evidence that P2Y4 nucleotide receptors are involved in the regulation of rat aortic smooth muscle cells by UTP and ATP. Br J Pharmacol 124: 703-710, 1998.
12. q signaling is involved in high blood pressure in both induced renal and genetic vascular smooth muscle-derived models of hypertension. Am J Physiol Heart Circ Physiol 293: H3072-H3079, 2007.
13. Hayabuchi Y, Dart C, Standen NB. Evidence for involvement of A-kinase anchoring protein in activation of rat arterial KATP channels by protein kinase A. J Physiol 536: 421-427, 2001.
14. Kim J, Ahn S, Rajagopal K, Lefkowitz RJ. Independent ß-arrestin2 and Gq/protein kinase Cq pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor. J Biol Chem 284: 11953-11962, 2009.
15. Kim J, Zhang L, Peppel K, Wu JH, Zidar DA, Brian L, DeWire SM, Exum ST, Lefkowitz RJ, Freedman NJ. ß-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration. Circ Res 103: 70-79, 2008.
16. Kohout TA, Lin FS, Perry SJ, Conner DA, Lefkowitz RJ. ß-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc Natl Acad Sci USA 98: 1601-1606, 2001.
17. Kubo T, Ibusuki T, Chiba S, Kambe T, Fukumori R. Altered mitogenactivated protein kinase activation in vascular smooth muscle cells from spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 29: 537-543, 2002.
18. Min J, Defea K. ß-arrestin-dependent actin reorganization: bringing the right players together at the leading edge. Mol Pharmacol 80: 760-768, 2011.
19. Miquel R, Gisbert R, Serna E, Perez-Vizcaino F, Anselmi E, Noguera MA, Ivorra MD, D’Ocon MP. Acute and chronic captopril, but not prazosin or nifedipine, normalize alterations in adrenergic intracellular Ca2+ handling observed in the mesenteric arterial tree of spontaneously hypertensive rats. J Pharmacol Exp Ther 313: 359-367, 2005.
20. Morris GE, Nelson CP, Brighton PJ, Standen NB, Challiss RA, Willets JM. Arrestins 2 and 3 differentially regulate ETA and P2Y2 receptor-mediated cell signaling and migration in arterial smooth muscle. Am J Physiol Cell Physiol 302: C723-C734, 2012.
21. Morris GE, Nelson CP, Everitt D, Brighton PJ, Standen NB, Challiss RA, Willets JM. G protein-coupled receptor kinase 2 and arrestin2 regulate arterial smooth muscle P2Y-purinoceptor signalling. Cardiovasc Res 89: 193-203, 2011.
22. Morris GE, Nelson CP, Standen NB, Challiss RA, Willets JM. Endothelin signalling in arterial smooth muscle is tightly regulated by G protein-coupled receptor kinase 2. Cardiovasc Res 85: 424-433, 2010.
23. 2+ and inositol 1,4,5-trisphosphate oscillation frequency. Receptor density versus agonist concentration. J Biol Chem 277: 35947-35960, 2002.
24. 1A angiotensin receptor. J Biol Chem 276: 37761-37768, 2001.
25. Penela P, Murga C, Ribas C, Tutor AS, Peregrin S, Mayor F Jr. Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease. Cardiovasc Res 69: 46-56, 2006.
26. 2+ channels: is membrane depolarization the signal? Circ Res 94: 97-104, 2004.
27. 2++ channels in mesenteric and skeletal arteries of SHR. Hypertension 40: 214-219, 2002.
28. Rosenbaugh EG, Savalia KK, Manickam DS, Zimmerman MC. Antioxidant- based therapies for angiotensin II-associated cardiovascular diseases. Am J Physiol Regul Integr Comp Physiol 304: R917-R928, 2013.
29. Schiffrin EL. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension 25: 1135-1143, 1995.
30. Sobolesky PM, Moussa O. The role of ß-arrestins in cancer. Prog Mol Biol Transl Sci 118: 395-411, 2013.
31. Strungs EG, Luttrell LM. Arrestin-dependent activation of ERK and Src family kinases. Hand Exp Pharmacol 219: 225-257, 2014.
32. Wilkie N, Ng LL, Boarder MR. Angiotensin II responses of vascular smooth muscle cells from hypertensive rats: enhancement at the level of p42 and p44 mitogen activated protein kinase. Br J Pharmacol 122: 209-216, 1997.
33. Willets JM, Brighton PJ, Mistry R, Morris GE, Konje JC, Challiss RA. Regulation of oxytocin receptor responsiveness by G protein-coupled receptor kinase 6 in human myometrial smooth muscle. Mol Endocrinol 23: 1272-1280, 2009.
34. Willets JM, Challiss RA, Nahorski SR. Non-visual GRKs: are we seeing the whole picture? Trends Pharmacol Sci 24: 626-633, 2003.